The statement said the scientific critique details why Merck disagrees with analysis of The Lancet and added that until a study this year, "data from Merck's clinical trials showed no significant difference in cardiovascular risk" of Vioxx.
US pharmaceutical giant Merck on Friday disputed the conclusion of the British medical weekly The Lancet that the arthritis drug Vioxx should have been pulled from the market four years earlier.
